Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD.

FIB-4 NAFLD hepatocellular carcinoma transient elastography

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
27 Apr 2022
Historique:
received: 04 04 2022
revised: 24 04 2022
accepted: 25 04 2022
entrez: 14 5 2022
pubmed: 15 5 2022
medline: 15 5 2022
Statut: epublish

Résumé

Background: The potential role of non-invasive tests (NITs) for liver fibrosis for hepatocellular carcinoma (HCC) prediction remains poorly known. Methods: Retrospective analysis of a NAFLD cohort from a single university hospital in Barcelona, Spain. Incidence rates and cumulative incidence for the overall cohort, as well as cirrhotic and non-cirrhotic patients were calculated. Logistic regression analyses were carried out to investigate risk factors of HCC. Results: From the entire cohort of 1040 patients, 996 patients (95.8%) were analyzed, in whom 35 cases of HCC were detected, of which 26 (72.4%) HCC incident cases were newly diagnosed during a median follow-up of 2.5 (1.9−3.6) years. Two-hundred and thirty-one (23.2%) were cirrhotic at baseline. With the exception of 2 (7.7%) cases of HCC, the rest were diagnosed in cirrhotic patients. Overall HCC cumulative incidence was 9.49 (95% CI 6.4−13.9) per 1000 person-years. The incidence rate for cirrhotic patients was 41.2 (95% CI 27.6−61.6) per 1000 person-years and 0.93 (95% CI 0.23−3.7) per 1000 person-years for patients without cirrhosis. Overall mortality was significantly higher amongst patients with HCC (4.4% vs. 30.8%, p < 0.001). In patients with available liver biopsy (n = 249, 25%), advanced fibrosis (F3−F4) was significantly associated with higher HCC incidence, but not steatosis, lobular inflammation, nor ballooning. In the overall cohort, FIB-4 ≥1.3 (HR 8.46, 95% CI 1.06−67.4, p = 0.044) and older age (HR 1.06, 95% CI 1.01−1.11, p = 0.025) were associated with increasing risk of HCC over time, whereas in cirrhotic patients predictors of HCC included decreasing values of albumin (HR 0.34, 95% CI 0.13−0.87, p = 0.024), platelets (HR 0.98, 95% CI 0.98−0.99, p = 0.001), and increasing values of liver stiffness (HR 1.03, 95% CI 1.00−1.06, p = 0.016). Conclusions: In a Spanish cohort of NAFLD patients, HCC was rare in non-cirrhotic patients. NITs might play a relevant role at predicting HCC.

Identifiants

pubmed: 35566592
pii: jcm11092466
doi: 10.3390/jcm11092466
pmc: PMC9103029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Hepatol. 2017 Nov 02;:
pubmed: 29150142
J Hepatol. 2022 Jan;76(1):247-248
pubmed: 34520785
Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10
pubmed: 33965578
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428
pubmed: 31028350
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Hepatol. 2016 Sep;65(3):570-8
pubmed: 27151181
J Clin Med. 2021 Oct 09;10(20):
pubmed: 34682759
J Hepatol. 2021 Sep;75(3):659-689
pubmed: 34166721
J Gastroenterol. 2017 Jan;52(1):104-112
pubmed: 27306373
Clin Gastroenterol Hepatol. 2022 Mar 23;:
pubmed: 35337981
Hepatol Commun. 2022 Apr;6(4):728-739
pubmed: 34783191
Clin Gastroenterol Hepatol. 2021 Apr;19(4):806-815.e5
pubmed: 32621970
Gastroenterology. 2019 May;156(6):1717-1730
pubmed: 30689971
Cancers (Basel). 2021 Sep 11;13(18):
pubmed: 34572795
PLoS One. 2018 Sep 27;13(9):e0204412
pubmed: 30260995
Hepatology. 2016 Mar;63(3):827-38
pubmed: 26599351
N Engl J Med. 2021 Oct 21;385(17):1559-1569
pubmed: 34670043
J Hepatol. 2021 Oct;75(4):786-794
pubmed: 34090928
Clin Gastroenterol Hepatol. 2022 Mar 17;:
pubmed: 35307595
Circulation. 2004 Jan 27;109(3):433-8
pubmed: 14744958
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
JHEP Rep. 2021 May 11;3(4):100305
pubmed: 34189448
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Liver Int. 2020 Mar;40(3):581-589
pubmed: 31749300
Medicine (Baltimore). 2021 Aug 6;100(31):e26835
pubmed: 34397849
J Hepatol. 2019 Sep;71(3):523-533
pubmed: 31145929

Auteurs

Mònica Pons (M)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.

Jesús Rivera-Esteban (J)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Ramiro Manzano (R)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.

Juan Bañares (J)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.

María Bermúdez (M)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.

Víctor Vargas (V)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Digestivas y Hepáticas (CIBERehd), 28029 Madrid, Spain.

Maria Teresa Salcedo-Allende (MT)

Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Pathology Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.

Lluís Castells (L)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Digestivas y Hepáticas (CIBERehd), 28029 Madrid, Spain.

Salvador Augustin (S)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Digestivas y Hepáticas (CIBERehd), 28029 Madrid, Spain.

Beatriz Mínguez (B)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Digestivas y Hepáticas (CIBERehd), 28029 Madrid, Spain.

Juan M Pericàs (JM)

Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari, 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Digestivas y Hepáticas (CIBERehd), 28029 Madrid, Spain.

Classifications MeSH